Advisory Board 11th Executive Congress on Translational Medicine, Biotech Innovation & Clinical Strategy
The Advisory Board supports the scientific direction, clinical relevance, academic quality, interdisciplinary scope, and international development of ECTMBICS 2027. Members contribute perspectives across translational medicine, biotechnology, clinical research, pharmaceutical innovation, digital health, regulatory science, healthcare systems, and the translation of research into patient benefit.
The Advisory Board is composed of experienced academics, clinicians, researchers, biotechnology professionals, healthcare specialists, and industry experts whose expertise aligns with the scientific themes of the congress.
Advisory Board Members
An international advisory panel representing expertise across biomedical innovation, gene editing, clinical research, digital medicine, regulatory science, healthcare systems, pharmaceutical development, and translational science.
Dr. Robert Langer
MIT, USA
Biotechnology, biomaterials, and drug delivery innovation.
Dr. Jennifer Doudna
UC Berkeley, USA
CRISPR gene editing and genome engineering.
Dr. Soumya Swaminathan
India
Global health, clinical research, and public health strategy.
Prof. Carl June
University of Pennsylvania, USA
CAR-T cell therapy and translational immunotherapy.
Dr. Özlem Türeci
BioNTech, Germany
mRNA therapeutics, oncology, and biotech leadership.
Dr. Katalin Karikó
Hungary / USA
mRNA science, vaccines, and therapeutic innovation.
Dr. Atul Gawande
Harvard, USA
Healthcare systems, surgery, public health, and care delivery.
Dr. Eric Topol
Scripps Research, USA
Digital medicine, AI in healthcare, and genomic medicine.
Prof. Patrick Vallance
United Kingdom
Clinical research, pharma strategy, and science policy.
Dr. Devi Shetty
Narayana Health, India
Healthcare innovation, cardiac care, and access models.
Dr. Feng Zhang
Broad Institute, USA
Genome editing, CRISPR systems, and molecular innovation.
Prof. Sir John Bell
University of Oxford, UK
Translational medicine, biomedical strategy, and innovation policy.
Dr. Margaret Hamburg
USA
Regulatory science, public health, and medical product oversight.
Dr. Ruxandra Draghia-Akli
Europe
Pharma innovation, R&D strategy, and biomedical leadership.
Advisory Board enquiries
Advisory Board appointments are generally made by invitation. Experienced researchers, clinicians, academics, and industry specialists may contact the Secretariat with a short professional profile and relevant areas of expertise for future consideration.